Table 2.
Population characteristics. *n = 57, seven patients did not have recent blood tests.
| Patients (n = 64) | |
|---|---|
| Demographic Characteristics | |
| Age, years | 69 ± 8 |
| Female, n (%) | 28 (45) |
| Cardiovascular Risk Factors | |
| Family history of coronary artery disease, n(%) | 22 (34) |
| Family history of stroke, n(%) | 8 (13) |
| Systemic arterial hypertension, n(%) | 49 (77) |
| Resistant hypertension, n(%) | 10 (16) |
| Hypercholesterolemia, n(%) | 46 (72) |
| Type 2 diabetes mellitus, n(%) | 16 (25) |
| Current smoker, n(%) | 28 (44) |
| Previous smoker, n(%) | 11 (27) |
| Body mass index (kg/cm2) | 25 ± 4 |
| Framingham risk score (%) | 12 (6–19) |
| High cardiovascular risk n(%) | 35 (55) |
| Previous acute coronary syndrome, n (%) | 12 (19) |
| Laboratory Parameters* | |
| White blood cells, 109/L | 7.2 (6–9) |
| Haemoglobin, g/dL | 14 (13–15) |
| AST, UI/L | 20 (16–25) |
| ALT, UI/L | 20 (15–27) |
| Platelets, 109/L | 205 (160–253) |
| Total cholesterol, mg/dL | 174 (155–196) |
| LDL cholesterol, mg/dL | 104 (85–122) |
| HDL cholesterol, mg/dL | 43 (38–50) |
| Triglyceridemia, mg/dL | 128 (95–161) |
| Glycemia, mg/dL | 99 (88–128) |
| Creatinine, mg/dL | 0.85 (0.73–1.04) |
| eGFR, mL/min | 72 (58–96) |
| Medical Therapy | |
| ACE inhibitors, n (%) | 20 (31) |
| Angiotensin Receptor Blockers, n (%) | 19 (30) |
| β-blockers, n(%) | 26 (41) |
| Calcium antagonists, n(%) | 16 (25) |
| Diuretics, n (%) | 13 (20) |
| Others vasodilators, n(%) | 4 (6) |
| Number of anti-hypertensive agents | 2 (1–5) |
| Statins, n(%) | 39 (61) |
| Antiplatelet agent - n(%) | 39 (61) |
| Oral diabetes medications, n(%) | 13 (20) |
| Insulin therapy, n (%) | 2 (3) |